Department of Surgery, Division of Surgical Oncology, Harbor UCLA Medical Center, Torrance, CA, USA.
Department of Pathology, Division of Cytopathology, Harbor UCLA Medical Center, Torrance, CA, USA.
Cancer Rep (Hoboken). 2018 Dec;1(4):e1132. doi: 10.1002/cnr2.1132. Epub 2018 Sep 16.
Pertuzumab has improved pathologic complete response rates when compared with other chemotherapeutics in the treatment of HER-2 positive breast cancer patients.
We sought to determine if axillary lymph node dissections (ALNDs) yielding at least the national standard of 10 lymph nodes is lower in patients who received neoadjuvant pertuzumab.
A retrospective database identified patients who underwent ALND for breast cancer. We compared the axillary lymph node retrieval rates in those who received or did not receive neoadjuvant pertuzumab. Of 139 breast cancer patients who underwent ALND, fewer than 10 axillary lymph nodes were found in 41.7% of patients who received neoadjuvant pertuzumab (P < 0.01) and 18.6% of patients who received neoadjuvant therapy without pertuzumab (P = 0.01).
Neoadjuvant chemotherapy was associated with a significantly lower rate of "adequate" ALNDs as defined by current guidelines. The patient subset that received neoadjuvant pertuzumab was more likely to have fewer than 10 axillary lymph nodes retrieved.
与其他化疗药物相比，曲妥珠单抗可提高 HER-2 阳性乳腺癌患者的病理完全缓解率。
我们旨在确定接受新辅助曲妥珠单抗治疗的患者的腋窝淋巴结清扫术（ALND）中至少获得 10 个淋巴结的比例是否较低。
回顾性数据库确定了接受 ALND 治疗乳腺癌的患者。我们比较了接受或未接受新辅助曲妥珠单抗治疗的患者的腋窝淋巴结检出率。在接受 ALND 的 139 例乳腺癌患者中，有 41.7%的接受新辅助曲妥珠单抗治疗的患者和 18.6%的未接受新辅助曲妥珠单抗治疗的患者发现腋窝淋巴结少于 10 个（P<0.01）。
新辅助化疗与目前指南定义的“足够”ALND 率显著降低相关。接受新辅助曲妥珠单抗治疗的患者亚组更有可能检出少于 10 个腋窝淋巴结。
